Results 61 to 70 of about 9,454,527 (233)

Prevalence of drug-herb and drug-supplement interactions in older adults : A cross-sectional survey [PDF]

, 2018
© British Journal of General PracticeBackground Polypharmacy is common among older adults, with increasing numbers also using prescription drugs with herbal medicinal products (HMPs) and dietary supplements.
Agbabiaka, Alsanad, Arcury, Batanero-Hernán, Blalock, Claire Goodman, Djuv, Farina, Ginter, Gonzàlez-Stuart, Ly, McLay, Neil H Spencer, Peklar, Porqueddu, Qato, Sabina Khanom, Schnabel, Steyn, Taofikat B Agbabiaka   +19 more
core   +2 more sources

Novel Strategies for Cancer Combat: Drug Combination Using Repurposed Drugs Induces Synergistic Growth Inhibition of MCF-7 Breast and HT-29 Colon Cancer Cells

Current Issues in Molecular Biology, 2022
Our group developed a new model of drug combination consisting of the use of antineoplastic drugs and different repurposed drugs, having demonstrated that antimalarial and central nervous system (CNS) drugs have a promising anticancer profile as ...
Diana Duarte, Inês Guerreiro, Nuno Vale
doaj   +1 more source

Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy [PDF]

, 2014
The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single ...
Bown, James L., Deeni, Yusuf Y., Goltsov, Alexey, Harrison, David J., Hu, Huizhong, Khalil, Hilal S., Kyriakidis, Stylianos, Langdon, Simon P., Soininen, Tero   +8 more
core   +6 more sources

Combination therapy in combating cancer

OncoTarget, 2017
Combination therapy, a treatment modality that combines two or more therapeutic agents, is a cornerstone of cancer therapy. The amalgamation of anti-cancer drugs enhances efficacy compared to the mono-therapy approach because it targets key pathways in a
R. Mokhtari, Tina S. Homayouni, N. Baluch, Evgeniya Morgatskaya, Sushil Kumar, Bikul Das, H. Yeger   +6 more
semanticscholar   +1 more source

Effect of FK506 in experimental organ transplantation. [PDF]

, 1988
FK506 is the most potent immunosuppressive agent known. Its toxicity is substantial in dogs, minor in rats, and unknown in subhuman primates. In small doses that are nontoxic even in dogs, it can be used in synergistic combination with cyclosporine ...
Casavilla, A., ChapChap, P., Demetris, J., Imventarza, O., Kahn, D., Makowka, L., Murase, N., Okuda, K., Podesta, L., Starzl, T.E., Todo, S., Ueda, Y.   +11 more
core  

Prevalence of psychoactive substances in Dutch and Belgian traffic [PDF]

, 2012
Objective: The purpose of this study was to compare the prevalence of psychoactive substances in general traffic in The Netherlands and Belgium. Method: Randomly selected car drivers and drivers of small vans in six police regions in The Netherlands and ...
Brookhuis, Karel, Hagenzieker, Marjan, Houwing, Sjoerd, Legrand, Sara-Ann, Mathijssen, René, Verstraete, Alain   +5 more
core   +2 more sources

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

Journal of Hematology & Oncology
Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have revolutionized the treatment paradigm of solid tumors.
Qing Wei, Peijing Li, Teng Yang, Jiayu Zhu, Lu Sun, Ziwen Zhang, Lu Wang, Xuefei Tian, Jiahui Chen, Can Hu, Junli Xue, Letao Ma, T. Shimura, Jianmin Fang, Jieer Ying, Peng Guo, Xiangdong Cheng   +16 more
semanticscholar   +1 more source

Energy Landscape Reveals the Underlying Mechanism of Cancer‐Adipose Conversion in Gene Network Models

Advanced Science
Cancer is a systemic heterogeneous disease involving complex molecular networks. Tumor formation involves an epithelial‐mesenchymal transition (EMT), which promotes both metastasis and plasticity of cancer cells.
Zihao Chen, Jia Lu, Xing‐Ming Zhao, Haiyang Yu, Chunhe Li   +4 more
doaj   +1 more source

A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors

Human Vaccines & Immunotherapeutics
Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are key components in immune checkpoint studies across various tumors, including those in the urinary tract.
Yongming Chen, Xiaojin Lu, Genyuan Peng, Shengjie Liu, Miao Wang, Huimin Hou   +5 more
doaj   +1 more source

Optimizing combination therapies with existing and future CML drugs. [PDF]

PLoS ONE, 2010
Small-molecule inhibitors imatinib, dasatinib and nilotinib have been developed to treat Chromic Myeloid Leukemia (CML). The existence of a triple-cross-resistant mutation, T315I, has been a challenging problem, which can be overcome by finding new ...
Allen A Katouli, Natalia L Komarova
doaj   +1 more source